Regulus Therapeutics' (RGLS) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS - Free Report) in a research note released on Monday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the biopharmaceutical company's stock.

A number of other equities research analysts also recently issued reports on the company. Canaccord Genuity Group lowered their price target on Regulus Therapeutics from $12.00 to $11.00 and set a buy rating for the company in a research report on Tuesday, March 19th. SVB Leerink initiated coverage on Regulus Therapeutics in a research note on Monday, March 18th. They set an outperform rating and a $6.00 price objective on the stock. Wells Fargo & Company boosted their price objective on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an equal weight rating in a research note on Wednesday, March 13th. StockNews.com initiated coverage on Regulus Therapeutics in a research note on Tuesday, April 16th. They set a sell rating on the stock. Finally, Leerink Partnrs restated an outperform rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Regulus Therapeutics has a consensus rating of Moderate Buy and a consensus price target of $7.25.

Regulus Therapeutics Stock Down 8.3 %

Shares of NASDAQ:RGLS traded down $0.22 during midday trading on Monday, reaching $2.43. The company's stock had a trading volume of 891,188 shares, compared to its average volume of 2,265,188. The firm has a market cap of $159.07 million, a price-to-earnings ratio of -1.57 and a beta of 1.59. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The business has a 50 day moving average price of $2.30 and a 200 day moving average price of $1.68.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). Sell-side analysts anticipate that Regulus Therapeutics will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RGLS. Victory Capital Management Inc. lifted its stake in shares of Regulus Therapeutics by 5.3% in the third quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company's stock worth $322,000 after acquiring an additional 11,701 shares in the last quarter. FMR LLC lifted its stake in shares of Regulus Therapeutics by 32.4% in the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company's stock worth $4,033,000 after acquiring an additional 716,000 shares in the last quarter. Finally, Vivo Capital LLC acquired a new position in shares of Regulus Therapeutics in the first quarter worth about $14,400,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.